CA125

CA125

CA125 詳細

Molecule Name
Mucin-16
分子の別称
CA125,CA-125,CA125MUC-16,FLJ14303,MUC16,mucin 16,mucin-16
Drug Development Progress
治験薬の数11
市販薬剤の数0
研究&開発段階Phase 3 Clinical
ターゲットの別称
Mucin-16 Short Isoform,Mucin-16 Long Isoform,Ovarian carcinoma antigen CA125,Ovarian cancer-related tumor marker CA125,MUC16,MUC-16,CA-125,Mucin 16, Cell Surface Associated,CA125,CA125 Ovarian Cancer Antigen,Mucin-16,CA-125 Antigen,FLJ14303
バックグランド
The CA125, also known as the MUC16, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. The CA 125 molecule is almost certainly a glycoprotein with a predominance of O-linkages. It is heterogeneous with regard to both size and charge, most likely due to continuous deglycosylation of side chains during its life-span in bodily fluids. It exists as a very large complex (perhaps as much as 4 million daltons) under natural conditions.

CA125 製品リスト

Species
  • Human(3)
  • Cynomolgus(2)
  • Mouse(1)
  • Rabbit(1)
  • Rat(1)
Tag
  • His Tag(5)
  • Fc Tag & Avi Tag(2)
  • His Tag & Avi Tag(1)
Host
  • HEK293(8)
Conjugate
  • Unconjugated(5)
  • Biotin-labeled(3)
Grade
  • RUO(8)
Low Endotoxin
  • Yes(2)
  • No(6)
You Have Viewed 1-8 Of 8 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
OregovomabB43.13Phase 3 ClinicalPaladin Pharma
Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms
詳細
EB-NK-FM (FRalpha/MUC16)EB-NK-FMPhase 2 ClinicalBeijing Biotech
Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms
詳細
EB-NK-MM (MSLN/MUC16)EB-NK-MMPhase 2 ClinicalBeijing Biotech
Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms
詳細
LBL-033LBL-033Phase 2 ClinicalNanjing Leadsbiolabs Co Ltd
Neoplasms
詳細
REGN-5668REGN-5668Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
詳細
UbamatamabREGN-4018Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
詳細
PRGN-3005PRGN-3005Phase 1 ClinicalPrecigen Inc
Esophageal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Uterine Cervical Neoplasms
詳細
GB-5267GB-5267Phase 1 ClinicalGenerate Biomedicines Inc
Ovarian Neoplasms
詳細
HWK-016HWK-016Phase 1 ClinicalWuxi Biologics Co Ltd
Endometrial Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms
詳細
JCAR-020JCAR-020Phase 1 ClinicalEureka Therapeutics Inc, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center
Solid tumours
詳細
Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy(Regeneron Pharmaceutical)27T-51; 27T51Phase 1 ClinicalRegeneron Pharmaceuticals Inc
Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms
詳細
Customer Reviews
  • E***e2025-08-07
    We used Acro Biosystems' recombinant Human CA125 / MUC16 protein (Catalog #CA5-H52H6) as a target antigen for antibody screening and downstream validation. The protein was employed in both ELISA and FACS assays. In ELISA, we observed strong, dose-dependent binding with minimal background, which enabled clear differentiation of candidate clones. For FACS, we used the protein to confirm surface staining specificity on engineered cell lines, and the results were consistent and reproducible. I was particularly impressed with the proteins high purity.